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Site-selective labelling of antibodies (Abs) can circumvent problems
from heterogeneity of conventional conjugation. Here, we evaluate
the industrially-applied chemoenzymatic ‘Q-tag’ strategy based on
transglutaminase-mediated (TGase) amide-bond formation in the
generation of 89Zr-radiolabelled antibody conjugates. We show
that, despite previously suggested high regioselectivity of TGases,
in the anti-Her2 Ab Herceptint more precise native MS indicates
only 70–80% functionalization at the target site (Q298H), in competition
with modification at other sites, such as Q3H critically close to the
CDR1 region.
Labelled antibodies (Abs) are vital clinical imaging tools and
therapeutic agents.1 Generating conjugated Abs through site-
specific conjugations that are more homogenously modified to
clinically relevant standards is essential for future therapeutic
use.2–4 Chemoenzymatic approaches can exploit the chemo-
selectivity and possible regioselectivity of even native residues
in antibodies and can therefore enable ‘remodelling’ of existing
antibodies.5–8 Transglutaminase (TGase) is one such enzyme
that has been suggested to catalyze transamidation reactions of
glutamine (Q) residues in a recognition sequence (the ‘Q-tag’)
over other glutamines in heavy chains of IgGs, thus facilitating
possible site-specific modification.9–11 As a consequence, TGase-
mediated ‘Q-tag’ modification of Abs has been widely explored to
generate Ab–drug conjugates,12,13 as well as labelled Abs,9,10,12,14
in both academia and industry.
Radiolabelled Abs find use in diagnostic imaging via
e.g. Positron Emission Tomography (PET) or Single Photon
Emission Computed Tomography (SPECT) as well as enabling
great progress in immunotherapy.15 Zirconium-89 in particular
has emerged as a powerful isotope for such applications. Its
favorable half-life (B3.3 days) is compatible with the slow
clearance rate of Abs in vivo, allowing longer imaging whilst
also providing high PET resolution.16 89Zr-labelled Abs therefore
represent a key demonstration system. Typically, 89Zr-labelled Abs
are generated by initial conjugation of a suitable metal-chelator
(e.g. siderophore deferoxamine (DFO)17) followed by radio-metal
chelation.18 With few exceptions19–21 attachment of a metal ion
chelator to Ab has been achieved by targeting nucleophilic
e-amines of several lysine (Lys) residues (Fig. 1A),22 resulting
in heterogeneity.
To improve homogeneity, protein engineering can be combined
with chemical modification to install and more-selectively label
additional cysteine (Cys) residues (Fig. 1B).19 Alternatively,
chemoenzymatic approaches can also be used to modify glycan
residues on Ab (Fig. 1C). Whilst these can reduce heterogeneity
Fig. 1 Strategies for 89Zr-radiolabelling of Abs. Traditional modification
methods based on Lys (A) typically generate heterogeneity. To reduce
heterogeneity, these have been extended by methods based on Cys (B),
glycans (C) or glutamine targeting (D) using chemical or chemoenzymatic
methods. (D) The ‘Q-tag’ system explored in this work has been previously
proposed to be exclusively selective for Q298H in antibodies.
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compared to traditional methods, they may still yield partial
heterogeneity due to, e.g.mixed glycosylation patterns or incom-
plete loading. Here, we show that an alternative, industrially-
applied, chemoenzymatic method – the ‘Q-tag’ system (Fig. 1D)23 –
allows successful generation of 89Zr-labelled Abs. Notably,
whilst this improves homogeneity, our study also reveals
previously unappreciated limits of Q-tag site-selectivity at sites
likely to directly impair function.
The transamidation activity of TGases, which naturally cross-
link Gln and Lys side-chains23 has been exploited previously to
modify several proteins24 including in generation of Ab–drug
(and other) conjugates.25–27 This method relies on a presumed
high, but in fact rarely fully-characterized selectivity for certain
peptide sequences containing Gln (so-called ‘Q-tags’). Amongst
these is the sequence PWEEQYNST11 in IgG Abs containing a
target Q298H residue (Herceptin numbering), found close to the
N-glycosylated N300H (Fig. 1D). As a consequence of the glyco-
sylation at site N300, site Q298 is typically sterically-occluded but
can be revealed by prior treatment with the amidase PNGase,
which converts glycosylated-N300 to D300 (Fig. 2).28
We applied a combined PNGase/TGase modification method
to generate 89Zr-labelled Abs with reduced heterogeneity in the
classical anti-Her2 Herceptint system. We designed a modular
process that would allow near-direct comparison with prior
results,29 through attachment of a DFO chelator to allow
radiolabelling with 89Zr. This also enabled additional modification
with other functional moieties (Fig. 2). To avoid metal-mediated
conjugation strategies, which might inhibit/interfere with
DFO chelation, we chose strain-promoted triazole formation30
for conjugation with a PEG–azidoamine10 as primary-amine
co-substrate for TGase (Fig. 2).
The protein substrate, deglycosylated (dg) Herceptin (dg-Her,
2), was generated by treating wild-type (wt) Herceptin (wt-Her, 1)
with PNGaseF,31 creating 2 as a D300H Asp-variant of Her.
Nearby and now accessible Q298H of dg-Her 2 was then con-
jugated to the azidoamine H2N–CH2CH2–(OCH2CH2)2–N3 (3)
using the TGase from Streptomyces mobaraensis to install an
azide residue into the side chain of Q298H (creating azido-Her 4)
for subsequent reaction with strained alkynes. Initial LCMS
under reducing, denaturing conditions (rLCMS) and reducing
SDS-PAGE analysis (ESI,† Table S1, method A), suggested
that deglycosylation and azide-incorporation steps proceeded
to completion, converting wt-Her 1 into desired products
dg-Her 2 and then azido-Her 4 (Fig. 2). Retained reactivity of
the azide moiety in azido-dg-Her 4 was confirmed using a
Cy3-dye-containing alkyne (ESI,† Fig S1). Notably, no modification
of the light chain was observed using these analytical methods
(Fig. 3B). Together these traditional modes of analysis proved
consistent with highly site-selective alterations guided by the
Q-tag sequence, as previously proposed.
Fig. 2 TGase-mediated, chemoenzymatic generation of 89Zr–Herceptin
conjugates. A modular strategy based on ‘Q-tag’ allowed incorporation of
variable moieties (see box). Sequential, chemoenzymatic remodeling using
PNGase and TGase and then chemical conjugation was directly monitored
by corresponding MS of heavy chain obtained under reducing, denaturing
conditions (rLCMS) prior to final 89Zr chelation (see also ESI,† Scheme S1).
Fig. 3 Precise monitoring of ‘Q-tag’ method reveals unexpected hetero-
geneity. (A) Reaction for TGase-mediated azide incorporation; (B) rLCMS
and (C) nMS (spectrum and zoom into +25 charge state) of mixed azide-
dg-Her 4 obtained using method A; (D) rLCMS and (E) nMS (spectrum and
zoom of +25 charge state) of mixed azido-dg-Her 4 using method C
reveals contaminant 4c bearing modification at Q3H. Note: nMS (C and E)
also show additional species (*)33 assigned to sequence variations (+176 Da),
consistent with prior analyses.6
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Prior work by us and others6,32 has demonstrated that
the heteromultimeric nature of monoclonal Abs can lead to
misleading quantitative analyses via rLCMS and that high
resolution native MS (nMS) of intact monoclonal antibody
conjugates can provide more precision and accuracy. nMS of
dg-Her 2 confirmed complete removal of N-glycans of wt-Her
1 (ESI,† Fig S2). However, analyses of azido-dg-Her 4 generated
under various conditions (ESI,† Table S1)25 unexpectedly
revealed mixtures of different Ab species with varied conjuga-
tion states (Fig. 3: 4a–c, azido copy numbers a = 1, b = 2, c = 3
plus unreacted 2). Together, these data revealed azido-dg-Her 4,
formed under these conditions, is not homogeneous (Fig. 3C
and E, also full MS data in ESI†).
Next, peptide mapping (tryptic-MS/MS) of azido-dg-Her 4
was used to dissect this surprising heterogeneity. This confirmed
primary incorporation of modified residue azido-EG3-Q298H at
target site Q298H (ESI,† Fig S3) could be achieved at levels of up
to 70% (70.2% relative to 4b). Notably, however, it also revealed
that attempts to drive further conversions (e.g.method C, higher
concentrations of Ab, amine, TGase) instead gave triply-modified
product 4c, bearing three azido moieties, at levels up to 14%
(Fig. 3). Use of reduced equivalents of 3 gave only poor conver-
sions (ESI,† Table S1, method E).
This was particularly surprising given the previously suggested
selectivity10 of TGase for Q298H and for the ‘Q-tag’ sequence.
Tryptic-MS/MS analysis of azido-Her 4 generated usingmethod C
allowed unambiguous identification of Q3H close to N-terminal
CDR1 epitope-binding region as a third conjugation site (ESI,†
Fig S4). Not only did this reveal limits of TGase-mediated ‘Q-tag’
conjugation, it also highlighted that the side-products contain
modifications that may directly interfere with epitope binding
due to proximity to CDRs.
Despite these unexpected and previously unappreciated
limitations in the ‘Q-tag’, we were nonetheless able to generate
useful target product mixtures (4) that were more homogeneous
(B80%) than those observed from typical chemical conjugations
(e.g. via Lys – see ESI,† Fig. S7 for typical). This, in turn, allowed
attachment of mono- and bi-functional moieties containing
chelate DFO (using 5), or DFO + peptide (using 6). These
modular DFO–alkyne 5 and DFO + IL1a-alkyne 6 reagents were
themselves constructed using HATU-mediated amide bond
formation (and maleimide conjugation in 6 – see ESI,†
Scheme S1). Bi-functional 6 additionally contains a cell-penetrating
peptide and nuclear localization sequence derived from hIL1a34 to
test the introduction of a model peptide module that could allow
interrogation of nuclear biomarkers in the future.35,36 These
constructs and conjugations also allowed us to test the modularity
of the TGase-based approach for building multi-functional Ab
systems, by straightforward alteration of the corresponding
alkyne-containing reaction partners. Reaction of 4 with both 5
or 6 proceeded with essentially full conversion (495%), as judged
by SDS-PAGE and rLCMS analysis (see ESI†), to yield conjugates
[DFO]2-dg-Her 7 and [DFO + IL1a]2-dg-Her 8, respectively, with
near-identical copy number distributionB2 (Fig. 2). This copy
number distribution was also confirmed by nMS analysis
with fully conjugated products as major species. Slight peak
broadening due to adventitious DFO-metal binding reduced
quantification precision by nMS, (ESI,† Fig. S5 and S6). Analysis
of conjugate stability over prolonged periods suggested good
stability for 7, but slow degradation of 8 (46 months, via
maleimide retro-Michael).
Radiolabelling of 7 and 8 via chelation with 89Zr,37 yielded
89Zr-labelled dg-Her variants 89Zr[DFO]2-dg-Her 9 and 89Zr
[DFO + IL1a]2-dg-Her 10 with radiochemical yields (RCY)
of 94  5% (n = 5) and 96  5% (n = 7), respectively (Fig. 2).
To allow side-by-side comparison with 89Zr–Herceptin conju-
gates obtained through conventional, random Lys-directed
modification38,39 we also generated37 [DFO]mix-Her 11 (ESI,†
Fig. S7). In contrast to site-selectively DFO-modified 8 and 9,
rLCMS analysis of [DFO]mix-Her 11 indicated high heterogeneity
in both heavy and light chains (ESI,† Fig. S7). Radiolabelling of
11 with 89Zr provided 89Zr[DFO]mix-Her 12 in RCY up to 98%.37
Retained biological functions of these Herceptint conjugates
7, 8, 11 were evaluated through determination of in vitro binding
affinities (KD) to Her2 using a saturation-binding assay (ESI,†
Fig. S8) and were not significantly different (P o 0.05) from wt
Herceptint. Importantly, 89Zr[DFO + IL1a]2-dg-Her 10 proved
highly stable in human serum at 37 1C, retaining radiolabel even
after 4 days of incubation (ESI,† Fig. S9) and suggesting promising
suitability for future in vivo use.
We have shown ‘Q-tag’ TGase-mediated Ab-conjugation yields
less homogeneous conjugates than previously thought. This, the
first precise analyses of intact TGase-generated Ab-conjugates
conducted with nMS, reveals limitations in selectivity of widely-
applied TGase. In the case of Herceptin, side products were
formed with unwanted modification at sites critically close to
CDRs. In preliminary experiments with murine anti-gH2AX anti-
body, (ESI,† Fig. S10), these limits of regioselectivity in the
‘Q-tag’-TGase method appear to be similar or worse. Our results
were obtained with single amine 3 deemed efficient in prior
studies;11 other amines may display altered selectivity. Indeed,
unexpected TGase-driven modification of human proteins with
endogenous amines has recently been noted,40 further high-
lighting the implications of TGase plasticity with respect to
amine and protein substrates.
Not withstanding these limitations, the method does allow
the creation of variants with improved homogeneity (B80%)
over traditional bioconjugations and enables a modular
approach, described here, with potential for adding multiple
functionalities in chelating moiety without any apparent gross
effect on function. Surprisingly, prior in vivo comparisons20 have
suggested that there are no differences between random attach-
ment methods and more selective methods; future work will
probe in vivo benefits of reduced heterogeneity.
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